BeiGene (ONC) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2024	Nov. 01, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-37686
Entity Registrant Name	BEIGENE, LTD.
Entity Incorporation, State or Country Code	E9
Entity Tax Identification Number	98-1209416
Entity Address, Street Address	c/o Mourant Governance Services (Cayman) Limited
Entity Address, Street Address Two	94 Solaris Avenue, Camana Bay
Entity Address, City	Grand Cayman
Entity Address, Country	KY
Entity Address, Postal Zip Code	KY1-1108
City Area Code	345
Local Phone Number	949-4123
Title of each class	American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol(s)	BGNE
Name of each exchange on which registered	NASDAQ
Entity Common Stock, Shares Outstanding		1,386,034,320
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001651308
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Total revenues	$ 1,001,599	$ 781,308	$ 2,682,417	$ 1,824,370
Gross profit	831,137	684,999	2,248,888	1,550,282
Operating expenses
Research and development	496,179	453,259	1,411,283	1,284,607
Selling, general and administrative	455,223	365,708	1,326,379	1,089,616
Total operating expenses	951,402	818,967	2,737,662	2,374,223
Loss from operations	(120,265)	(133,968)	(488,774)	(823,941)
Interest income, net	10,643	26,649	40,028	57,735
Other income, net	11,318	336,657	1,096	291,142
(Loss) income before income taxes	(98,304)	229,338	(447,650)	(475,064)
Income tax expense	23,046	13,925	45,255	39,091
Net (loss) income	$ (121,350)	$ 215,413	$ (492,905)	$ (514,155)
(Loss) earnings per share
Basic (in dollars per share)	$ (0.09)	$ 0.16	$ (0.36)	$ (0.38)
Diluted (in dollars per share)	$ (0.09)	$ 0.15	$ (0.36)	$ (0.38)
Weighted-average shares outstanding—basic (in shares)	1,376,751,873	1,360,716,279	1,361,216,763	1,358,392,470
Weighted-average shares outstanding— diluted (in shares)	1,376,751,873	1,390,331,833	1,361,216,763	1,358,392,470
(Loss) earnings per American Depositary Share (“ADS”)
Basic (in dollars per share)	$ (1.15)	$ 2.06	$ (4.71)	$ (4.92)
Diluted (in dollars per share)	$ (1.15)	$ 2.01	$ (4.71)	$ (4.92)
Weighted-average ADSs outstanding - basic (in shares)	105,903,990	104,670,483	104,708,982	104,491,728
Weighted-average ADSs outstanding - diluted (in shares)	105,903,990	106,948,603	104,708,982	104,491,728
Product revenue, net
Revenues
Total revenues	$ 993,447	$ 595,290	$ 2,661,511	$ 1,559,326
Cost of sales - product	170,462	96,309	433,529	274,088
Collaboration revenue
Revenues
Total revenues	$ 8,152	$ 186,018	$ 20,906	$ 265,044

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net (loss) income	$ (121,350)	$ 215,413	$ (492,905)	$ (514,155)
Other comprehensive income (loss), net of tax of nil:
Foreign currency translation adjustments	56,747	(2,559)	15,348	(75,732)
Pension liability adjustments	202	0	608	0
Unrealized holding income (loss), net	0	1,315	(35)	8,218
Comprehensive loss attributable to BeiGene, Ltd.	$ (64,401)	$ 214,169	$ (476,984)	$ (581,669)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS ¥ in Thousands, $ in Thousands	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Current assets:
Cash and cash equivalents	$ 2,701,933	$ 3,171,800
Accounts receivable, net	569,047	358,027
Inventories, net	431,676	416,122
Prepaid expenses and other current assets	209,080	257,465
Total current assets	3,911,736	4,203,414
Property, plant and equipment, net	1,562,965	1,324,154
Operating lease right-of-use assets	101,046	95,207
Intangible assets, net	53,939	57,138
Other non-current assets	201,174	125,362
Total non-current assets	1,919,124	1,601,861
Total assets	5,830,860	5,805,275
Current liabilities:
Accounts payable	307,532	315,111
Accrued expenses and other payables	717,343	693,731
Tax payable	14,880	22,951
Operating lease liabilities, current portion	17,707	21,950
Research and development cost share liability, current portion	104,067	68,004
Short-term debt	863,803	688,366
Total current liabilities	2,025,332	1,810,113
Non-current liabilities:
Long-term bank loans	187,513	197,618
Operating lease liabilities, non-current portion	32,454	22,251
Deferred tax liabilities	15,935	16,494
Research and development cost share liability, non-current portion	82,985	170,662
Other long-term liabilities	50,568	50,810
Total non-current liabilities	369,455	457,835
Total liabilities	2,394,787	2,267,948
Commitments and contingencies
Shareholders’ equity:
Ordinary shares, $0.0001 par value per share; 9,500,000,000 shares authorized; 1,386,034,320 and 1,359,513,224 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	138	135
Additional paid-in capital	11,974,415	11,598,688
Accumulated other comprehensive loss	(83,525)	(99,446)
Accumulated deficit	(8,454,955)	(7,962,050)
Total shareholders’ equity	3,436,073	3,537,327
Total liabilities and shareholders’ equity	$ 5,830,860	$ 5,805,275

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Ordinary shares
Ordinary shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized (in shares)	9,500,000,000	9,500,000,000
Ordinary shares, shares issued (in shares)	1,386,034,320	1,359,513,224
Ordinary shares, shares outstanding (in shares)	1,386,034,320	1,359,513,224

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities:
Net loss	$ (492,905)	$ (514,155)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	121,516	63,856
Share-based compensation expenses	334,001	274,697
Acquired in-process research and development	0	15,000
Amortization of research and development cost share liability	(51,614)	(38,569)
Gain on BMS termination settlement	0	(362,917)
Other items, net	11,516	13,830
Changes in operating assets and liabilities:
Accounts receivable	(203,744)	(143,511)
Inventories	(12,112)	(52,371)
Other assets	9,505	(17,598)
Accounts payable	13,536	31,366
Accrued expenses and other payables	54,638	50,089
Deferred revenue	477	(255,587)
Other liabilities	(605)	55
Net cash used in operating activities	(215,791)	(935,815)
Investing activities:
Purchases of property, plant and equipment	(400,183)	(404,937)
Purchase of intangible asset	(4,674)	(9,413)
Proceeds from sale or maturity of investments	2,655	567,519
Purchase of in-process research and development	(31,800)	(15,000)
Other investing activities	(20,743)	(15,581)
Net cash (used in) provided by investing activities	(454,745)	122,588
Financing activities:
Proceeds from long-term loan	9,053	22,502
Repayment of long-term loan	(17,581)	(8,462)
Proceeds from short-term loans	324,412	162,614
Repayment of short-term loans	(157,490)	(159,576)
Proceeds from option exercises and employee share purchase plan	36,578	52,352
Other financing activities	3,000	0
Net cash provided by financing activities	197,972	69,430
Effect of foreign exchange rate changes, net	8	(50,348)
Net decrease in cash, cash equivalents, and restricted cash	(472,556)	(794,145)
Cash, cash equivalents, and restricted cash at beginning of period	3,185,984	3,875,037
Cash, cash equivalents, and restricted cash at end of period	2,713,428	3,080,892
Supplemental cash flow information:
Cash and cash equivalents	2,701,933	3,067,336
Short-term restricted cash	9,284	11,548
Long-term restricted cash	2,211	2,008
Income taxes paid	54,778	42,516
Interest expense paid	38,162	15,893
Supplemental non-cash information:
Capital expenditures included in accounts payable and accrued expenses	75,317	107,611
Increase in equity investment from deconsolidation of a subsidiary	40,798	0
Acquired intangible asset included in accounts payable	$ 0	$ 9,384

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at the beginning of period (in shares) at Dec. 31, 2022		1,356,140,180
Balance at the beginning of period at Dec. 31, 2022	$ 4,383,355	$ 135	$ 11,540,979	$ (77,417)	$ (7,080,342)
Increase (Decrease) in Stockholders' Equity
Use of shares reserved for share option exercises (in shares)		(98,774)
Exercise of options, ESPP and release of RSUs (in shares)		6,610,695
Exercise of options, ESPP and release of RSUs	28,657	$ 1	28,656
Share-based compensation	75,322		75,322
Other comprehensive (loss) income	18,403			18,403
Net (loss) income	(348,431)				(348,431)
Balance at the end of period (in shares) at Mar. 31, 2023		1,362,652,101
Balance at the end of period at Mar. 31, 2023	4,157,306	$ 136	11,644,957	(59,014)	(7,428,773)
Balance at the beginning of period (in shares) at Dec. 31, 2022		1,356,140,180
Balance at the beginning of period at Dec. 31, 2022	4,383,355	$ 135	11,540,979	(77,417)	(7,080,342)
Increase (Decrease) in Stockholders' Equity
Net (loss) income	(514,155)
Balance at the end of period (in shares) at Sep. 30, 2023		1,352,997,624
Balance at the end of period at Sep. 30, 2023	3,763,234	$ 135	11,502,527	(144,931)	(7,594,497)
Balance at the beginning of period (in shares) at Mar. 31, 2023		1,362,652,101
Balance at the beginning of period at Mar. 31, 2023	4,157,306	$ 136	11,644,957	(59,014)	(7,428,773)
Increase (Decrease) in Stockholders' Equity
Issuance of shares reserved for share option exercises & Proceeds from issuance of ordinary shares, net of cost (in shares)		220,116
Exercise of options, ESPP and release of RSUs (in shares)		13,379,119
Exercise of options, ESPP and release of RSUs	3,692	$ 1	3,691
Share-based compensation	103,371		103,371
Other comprehensive (loss) income	(84,673)			(84,673)
Net (loss) income	(381,137)				(381,137)
Balance at the end of period (in shares) at Jun. 30, 2023		1,376,251,336
Balance at the end of period at Jun. 30, 2023	3,798,559	$ 137	11,752,019	(143,687)	(7,809,910)
Increase (Decrease) in Stockholders' Equity
Use of shares reserved for share option exercises (in shares)		(4,689,438)
Exercise of options, ESPP and release of RSUs (in shares)		4,708,834
Exercise of options, ESPP and release of RSUs	17,419	$ 0	17,419
Cancellation of ordinary shares (in share)		(23,273,108)
Cancellation of ordinary shares	(362,917)	$ (2)	(362,915)
Share-based compensation	96,004		96,004
Other comprehensive (loss) income	(1,244)			(1,244)
Net (loss) income	215,413				215,413
Balance at the end of period (in shares) at Sep. 30, 2023		1,352,997,624
Balance at the end of period at Sep. 30, 2023	$ 3,763,234	$ 135	11,502,527	(144,931)	(7,594,497)
Balance at the beginning of period (in shares) at Dec. 31, 2023	1,359,513,224	1,359,513,224
Balance at the beginning of period at Dec. 31, 2023	$ 3,537,327	$ 135	11,598,688	(99,446)	(7,962,050)
Increase (Decrease) in Stockholders' Equity
Use of shares reserved for share option exercises (in shares)		(3,634,952)
Exercise of options, ESPP and release of RSUs (in shares)		3,646,097
Exercise of options, ESPP and release of RSUs	15,663	$ 1	15,662
Share-based compensation	88,667		88,667
Deconsolidation of a subsidiary	2,052		2,052
Other comprehensive (loss) income	(32,198)			(32,198)
Net (loss) income	(251,150)				(251,150)
Balance at the end of period (in shares) at Mar. 31, 2024		1,359,524,369
Balance at the end of period at Mar. 31, 2024	$ 3,360,361	$ 136	11,705,069	(131,644)	(8,213,200)
Balance at the beginning of period (in shares) at Dec. 31, 2023	1,359,513,224	1,359,513,224
Balance at the beginning of period at Dec. 31, 2023	$ 3,537,327	$ 135	11,598,688	(99,446)	(7,962,050)
Increase (Decrease) in Stockholders' Equity
Other comprehensive (loss) income	15,921
Net (loss) income	$ (492,905)
Balance at the end of period (in shares) at Sep. 30, 2024	1,386,034,320	1,386,034,320
Balance at the end of period at Sep. 30, 2024	$ 3,436,073	$ 138	11,974,415	(83,525)	(8,454,955)
Balance at the beginning of period (in shares) at Mar. 31, 2024		1,359,524,369
Balance at the beginning of period at Mar. 31, 2024	3,360,361	$ 136	11,705,069	(131,644)	(8,213,200)
Increase (Decrease) in Stockholders' Equity
Issuance of shares reserved for share option exercises & Proceeds from issuance of ordinary shares, net of cost (in shares)		2,418,936
Exercise of options, ESPP and release of RSUs (in shares)		17,158,596
Exercise of options, ESPP and release of RSUs	4,492	$ 1	4,491
Share-based compensation	130,637		130,637
Other comprehensive (loss) income	(8,830)			(8,830)
Net (loss) income	(120,405)				(120,405)
Balance at the end of period (in shares) at Jun. 30, 2024		1,379,101,901
Balance at the end of period at Jun. 30, 2024	3,366,255	$ 137	11,840,197	(140,474)	(8,333,605)
Increase (Decrease) in Stockholders' Equity
Use of shares reserved for share option exercises (in shares)		1,944,995
Exercise of options, ESPP and release of RSUs (in shares)		4,987,424
Exercise of options, ESPP and release of RSUs	19,522	$ 1	19,521
Share-based compensation	114,697		114,697
Other comprehensive (loss) income	56,949			56,949
Net (loss) income	$ (121,350)				(121,350)
Balance at the end of period (in shares) at Sep. 30, 2024	1,386,034,320	1,386,034,320
Balance at the end of period at Sep. 30, 2024	$ 3,436,073	$ 138	$ 11,974,415	$ (83,525)	$ (8,454,955)

Description of Business, Basis

Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies	Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies Description of business BeiGene, Ltd. (the “Company”, “BeiGene”, “it”, “its”) is a global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. The Company currently has three approved medicines that were internally discovered and developed, including BRUKINSA ® (zanubrutinib), a small molecule inhibitor of Bruton’s Tyrosine Kinase (“BTK”) for the treatment of various blood cancers; TEVIMBRA ® (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX ® (pamiparib), a selective small molecule inhibitor of PARP1 and PARP2. The Company markets BRUKINSA in the United States (“U.S.”), the People’s Republic of China (“China” or the “PRC”), the European Union (“EU”), the United Kingdom (“UK”), Canada, Australia, and additional international markets; TEVIMBRA (tislelizumab) in the U.S., EU and China; and PARTRUVIX in China. By leveraging its strong commercial capabilities, the Company has in-licensed the rights to distribute additional approved medicines for the China market. Supported by its global clinical development and commercial capabilities, the Company has entered into collaborations with world-leading biopharmaceutical companies such as Amgen Inc. (“Amgen”) and Beijing Novartis Pharma Co., Ltd. (“Novartis”) to develop and commercialize innovative medicines. Basis of presentation and consolidation The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of shareholders’ equity for the three and nine months ended September 30, 2024 and 2023, and the related footnote disclosures are unaudited. The accompanying unaudited interim condensed financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including guidance with respect to interim financial information and in conformity with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and determining the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates. Recent accounting pronouncements New accounting standards which have not yet been adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which amended ASC 280. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. Single reportable segment entities are required to comply with all ASC 280 disclosure requirements. The Company will disclose descriptive information as required under ASC 280 and reference the consolidated financial statements in the segment and geographic information footnote for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance. Significant accounting policies For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited interim condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2023. There have been no material changes to the Company’s significant accounting policies as of and for the nine months ended September 30, 2024, as compared to the significant accounting policies described in the Annual Report.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company measures certain financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows: Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the asset or liability. The Company considers an active market to be one in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis, and considers an inactive market to be one in which there are infrequent or few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. The following tables present the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis using the above input categories as of September 30, 2024 and December 31, 2023: Quoted Price in Active Market for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs As of September 30, 2024 (Level 1) (Level 2) (Level 3) $ $ $ Cash equivalents Money market funds 966,088 — — Prepaid expenses and other current assets: Convertible debt instrument — — 3,170 Other non-current assets (Note 4): Equity securities with readily determinable fair values 1,889 160 — Convertible debt instrument — — 4,995 Total 967,977 160 8,165 Quoted Price in Active Market for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs As of December 31, 2023 (Level 1) (Level 2) (Level 3) $ $ $ Cash equivalents Money market funds 1,052,149 — — Prepaid expenses and other current assets: U.S. Treasury securities 2,600 — — Convertible debt instrument — — 4,668 Other non-current assets (Note 4): Equity securities with readily determinable fair values 3,046 542 — Convertible debt instrument — — 4,215 Total 1,057,795 542 8,883 The Company’s cash equivalents are highly liquid investments with original maturities of 3 months or less. The Company’s investments in available-for-sale debt securities include U.S. Treasury securities. The Company determines the fair value of cash equivalents and available-for-sale debt securities using a market approach based on quoted prices in active markets. The Company’s equity securities carried at fair value consist of holdings in common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (“Leap”), a publicly-traded biotechnology company. The common stock investment is measured and carried at fair value and classified as a Level 1 investment. The warrants to purchase additional shares of common stock are measured using the Black-Scholes option-pricing valuation model and classified as a Level 2 investment. Refer to Note 4, Restricted Cash and Investments for details of the determination of the carrying amount of private equity investments without readily determinable fair values and equity method investments. The Company holds convertible notes issued by private biotech companies. The Company elected the fair value option method of accounting for the convertible notes. Accordingly, the convertible notes are remeasured at fair value on a recurring basis using Level 3 inputs, with any changes in the fair value option recorded in other income, net. The Company recorded losses on fair value adjustment of $1,802 and $1,664 for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024 and December 31, 2023, the Company held time deposits of $15,000 and $42,852 that were classified as cash equivalents, respectively. As of September 30, 2024 and December 31, 2023, the fair values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and short-term debt approximated their carrying values due to their short-term nature. Long-term bank loans approximate their fair value due to the fact that the related interest rates approximate the rates currently offered by financial institutions for similar debt instrument of comparable maturities.

Collaborative and Licensing Arr

Collaborative and Licensing Arrangements	9 Months Ended
	Sep. 30, 2024
Research and Development [Abstract]
Collaborative and Licensing Arrangements	Collaborative and Licensing Arrangements The Company has entered into collaborative arrangements for the research and development, manufacture and/or commercialization of medicines and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license internally developed products and drug candidates to other parties, in-licenses of products and drug candidates from other parties, and profit- and cost-sharing arrangements. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing and reimbursement arrangements, royalty payments, and profit sharing. For detailed descriptions of each arrangement, see the Company’s Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission on February 26, 2024. Out-Licensing Arrangements For the three and nine months ended September 30, 2024, the Company’s collaboration revenue consisted primarily of revenue generated under the Novartis broad markets agreement. For the three and nine months ended September 30, 2023, the Company’s collaboration revenue primarily consisted of the recognition of previously deferred revenue from its former collaboration agreements with Novartis for tislelizumab and ociperlimab. The following table summarizes total collaboration revenue recognized for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenue from Collaborators $ $ $ $ Research and development service revenue — 59,052 — 79,432 Right to access intellectual property revenue — 51,978 — 104,475 Material rights revenue — 71,980 — 71,980 Other 8,152 3,008 20,906 9,157 Total 8,152 186,018 20,906 265,044 Novartis Tislelizumab Collaboration and License In September 2023, the Company and Novartis agreed to mutually terminate the tislelizumab collaboration and license agreement. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize tislelizumab with no royalty payments due to Novartis. Novartis may continue its ongoing clinical trials and has the ability to conduct future combination trials with tislelizumab subject to BeiGene’s approval. BeiGene agreed to provide Novartis with ongoing clinical supply of tislelizumab to support its clinical trials. Pursuant to the termination agreement, Novartis agreed to provide transition services to the Company to enable key aspects of the tislelizumab development and commercialization plan to proceed without disruption, including manufacturing, regulatory, safety and clinical support. Upon termination of the agreement in September 2023, there were no further performance obligations, and the remaining deferred revenue balance associated with the tislelizumab R&D services was recognized in full. Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement In July 2023, the Company and Novartis mutually agreed to terminate the ociperlimab option, collaboration and license agreement. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize ociperlimab. Upon termination the Company had no further performance obligations under the collaboration, and all remaining deferred revenue balances were recognized in full. The China broad markets agreement remains in place. The following table summarizes collaboration revenue recognized in connection with the China broad markets agreement for the three and nine months ended September 30, 2024 and the terminated ociperlimab option, collaboration and license agreement for the three and nine months ended September 30, 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 3,569 — 7,153 Right to access intellectual property revenue — 51,978 — 104,475 Material rights revenue — 71,980 71,980 China broad markets agreement 5,154 2,954 13,655 5,590 Total 5,154 130,481 13,655 189,198 In-Licensing Arrangements - Commercial Amgen During the three and nine months ended September 30, 2024 and 2023, the Company recorded the following amounts related to its collaboration arrangement with Amgen. For a detailed description of the arrangement and related rights and obligation, see the Company’s Form 10-K for the year ended December 31, 2023 filed on February 26, 2024. Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Research and development expense 17,015 16,321 52,981 39,595 Amortization of research and development cost share liability 16,575 15,900 51,614 38,569 Total amount due to Amgen for BeiGene’s portion of the development funding 33,590 32,221 104,595 78,164 As of September 30, 2024 $ Remaining portion of development funding cap 379,057 As of September 30, 2024 and December 31, 2023, the research and development cost share liability recorded in the Company’s balance sheet was as follows: As of September 30, December 31, 2024 2023 $ $ Research and development cost share liability, current portion 104,067 68,004 Research and development cost share liability, non-current portion 82,985 170,662 Total research and development cost share liability 187,052 238,666 The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three and nine months ended September 30, 2024 and 2023 as follows: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Cost of sales - product 10,278 3,159 28,437 4,343 Research and development (269) 431 (1,413) 1,743 Selling, general and administrative (21,641) (14,679) (60,894) (44,067) Total (11,632) (11,089) (33,870) (37,981) The Company purchases commercial inventory from Amgen to distribute in China. Inventory purchases amounted to $43,061 and $152,940 during the three and nine months ended September 30, 2024, respectively, and $18,746 and $58,023 during the three and nine months ended September 30, 2023, respectively. Net amounts payable to Amgen was $89,482 and $55,474 as of September 30, 2024 and December 31, 2023, respectively. In-Licensing Arrangements - Development The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing arrangements, royalty payments, and profit sharing. Upfront and milestone payments incurred under these arrangements for the three and nine months ended September 30, 2024 and 2023 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or term of the commercialization agreements. Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Payments due to collaboration partners Classification $ $ $ $ Upfront payments Research and development expense — 15,000 27 15,000 Development milestones incurred Research and development expense 5,000 — 51,500 — Regulatory and commercial milestone payments Intangible asset — 9,379 — 18,612 Total 5,000 24,379 51,527 33,612

Restricted Cash and Investments

Restricted Cash and Investments	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Restricted Cash and Investments	Restricted Cash and Investments Restricted Cash The Company’s restricted cash primarily consists of RMB-denominated cash deposits held in designated bank accounts for collateral for letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction. Restricted cash as of September 30, 2024 and December 31, 2023 was as follows: As of September 30, December 31, 2024 2023 $ $ Short-term restricted cash 9,284 11,473 Long-term restricted cash 2,211 2,711 Total 11,495 14,184 In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from its offering on the STAR Market of the Shanghai Stock Exchange (the “STAR Offering”) in strict compliance with the planned uses as disclosed in the PRC prospectus as well as those disclosed in the Company’s proceeds management policy approved by the board of directors. As of September 30, 2024, the Company had cash remaining related to the STAR Offering proceeds of $787,147. Investments in Equity Securities The following table summarizes the Company’s investments in equity securities: As of September 30, December 31, 2024 2023 $ $ Equity securities with readily determinable fair values 1 Fair value of Leap common stock 1,889 3,046 Fair value of Leap warrants 160 542 Equity securities without readily determinable fair values Pi Health, Inc. 2 40,798 — Other 55,159 55,860 Equity-method investments 35,233 25,981 Total 133,239 85,429 1 Represents common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (“Leap”). The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other income, net. 2 In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $38,063. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $40,798 and cash consideration of $1,000. The transaction resulted in a pre-tax gain of $3,735 recorded within other income, net during the nine months ended September 30, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company’s continuing operations. The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other income, net for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Equity securities with readily determinable fair values 494 (2,291) (1,539) (2,927) Equity securities without readily determinable fair values — (5,522) (797) (4,441) Equity-method investments (2,936) (2,675) (7,809) (5,299)

Inventories, Net

Inventories, Net	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net The Company’s inventories, net consisted of the following: As of September 30, December 31, 2024 2023 $ $ Raw materials 147,297 148,772 Work in process 61,985 39,098 Finished goods 222,394 228,252 Total inventories, net 431,676 416,122

Property, Plant and Equipment,

Property, Plant and Equipment, Net	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, net are recorded at cost and consisted of the following: As of September 30, December 31, 2024 2023 $ $ Land 65,485 65,485 Building 608,004 231,656 Manufacturing equipment 249,371 186,856 Laboratory equipment 236,085 205,349 Leasehold improvement 60,728 60,124 Software, electronics and office equipment 83,814 83,281 Property, plant and equipment, at cost 1,303,487 832,751 Less: accumulated depreciation (366,165) (249,212) Construction in progress 625,643 740,615 Property, plant and equipment, net 1,562,965 1,324,154 The Company has made a significant investment in its newly opened manufacturing and R&D center in Hopewell, New Jersey. In the three months ended September 30, 2024, $256,570 of assets were placed into service. As of September 30, 2024, the Company had construction in progress of $473,833 related to the Hopewell facility, the majority of which will be put into service in the first quarter of 2025. In March 2024, the Company acquired a land use right and the facility currently being constructed on the land for $75,986. The Company plans to complete the construction of the facility and build a research and development center on the land. Based on the relative fair values of the land use right and construction in progress, $29,721 of the total purchase price was allocated to the land use right and $46,265 was allocated to the construction in progress. In May 2024, the Company acquired additional construction in progress in connection with the properties for $23,443. As of September 30, 2024, title of the land use right was being transitioned to the Company. As such, the purchase price allocated to the land use right was recorded as a long-term prepaid as of September 30, 2024 and will be transferred to operating lease right-of-use asset upon the closing of the transaction. Depreciation expense was $70,028 and $117,892 for the three and nine months ended September 30, 2024, respectively, and $19,242 and $59,574 for the three and nine months ended September 30, 2023, respectively. Included within depreciation expense for the three and nine months ended September 30, 2024 is $41,808 of accelerated depreciation expense resulting from the move of production to more efficient, larger scale equipment for tislelizumab.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets as of September 30, 2024 and December 31, 2023 are summarized as follows: As of September 30, 2024 December 31, 2023 Gross Gross carrying Accumulated Intangible carrying Accumulated Intangible amount amortization assets, net amount amortization assets, net $ $ $ $ $ $ Finite-lived intangible assets: Developed products 64,811 (11,465) 53,346 64,274 (7,807) 56,467 Other 8,987 (8,394) 593 8,987 (8,316) 671 Total finite-lived intangible assets 73,798 (19,859) 53,939 73,261 (16,123) 57,138 Developed products represent post-approval milestone payments under license and commercialization agreements. The Company is amortizing the developed products over the remainder of the respective product patent or the term of the commercialization agreements. Amortization expense for developed products is included in cost of sales - product in the accompanying consolidated statements of operations. Amortization expense for other intangible assets is included in selling, general and administrative expense in the accompanying consolidated statements of operations. The weighted-average life for each finite-lived intangible assets is approximately 12 years. Amortization expense was as follows: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Amortization expense - Cost of sales - product 1,186 981 3,546 2,620 Amortization expense - Selling, general and administrative 78 1,287 78 1,662 Total 1,264 2,268 3,624 4,282 Estimated amortization expense for each of the five succeeding years and thereafter, as of September 30, 2024 is as follows: Year Ending December 31, Cost of Sales - Product Selling, General and Administrative Total $ $ $ 2024 (remainder of year) 1,204 17 1,221 2025 4,812 67 4,879 2026 4,812 67 4,879 2027 4,812 67 4,879 2028 4,812 67 4,879 2029 and thereafter 32,894 308 33,202 Total 53,346 593 53,939

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income tax expense was $23,046 and $45,255 for the three and nine months ended September 30, 2024, respectively, and $13,925 and $39,091 for the three and nine months ended September 30, 2023, respectively. The income tax expense for the three and nine months ended September 30, 2024 and 2023 was primarily attributable to current U.S. tax expense determined after other special tax deductions and research and development tax credits, current Switzerland tax expense based on year to date earnings, and current China tax expense due to certain non-deductible expenses. On a quarterly basis, the Company evaluates the realizability of deferred tax assets by jurisdiction and assesses the need for a valuation allowance. In assessing the realizability of deferred tax assets, the Company considers historical profitability, evaluation of scheduled reversals of deferred tax liabilities, projected future taxable income and tax-planning strategies. Valuation allowances have been provided on deferred tax assets where, based on all available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. After consideration of all positive and negative evidence, as of September 30, 2024, the Company will maintain a full valuation allowance against its net deferred tax assets. As of September 30, 2024, the Company had gross unrecognized tax benefits of $17,592. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly change within the next 12 months. The Company’s reserve for uncertain tax positions increased by $1,788 and $3,328 in the three and nine months ended September 30, 2024 primarily due to U.S. federal and state tax credits and incentives.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	9 Months Ended
	Sep. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information Prepaid expenses and other current assets consist of the following: As of September 30, December 31, 2024 2023 $ $ Prepaid research and development costs 60,227 60,476 Prepaid taxes 25,048 37,320 Other receivables 33,967 37,859 Prepaid manufacturing cost 28,849 42,066 Prepaid general and administrative expenses 16,183 14,619 Short-term restricted cash 9,284 11,473 Deposits 7,860 26,753 Prepaid insurance 6,180 8,872 Other current assets 21,482 18,027 Total 209,080 257,465 Other non-current assets consist of the following: As of September 30, December 31, 2024 2023 $ $ Prepayment of property and equipment 1 35,963 4,144 Prepaid supply cost 12,779 18,122 Rental deposits and other 9,180 8,195 Prepaid VAT 2,807 2,546 Long-term restricted cash 2,211 2,711 Long-term investments (Note 4) 138,234 89,644 Total 201,174 125,362 1 Includes payment for acquired land use right that was in the process of being transitioned to the Company as of September 30, 2024 (See Note 6). Accrued expenses and other payables consist of the following: As of September 30, December 31, 2024 2023 $ $ Revenue rebates and returns related 213,747 139,936 Compensation related 211,856 217,803 External research and development activities related 112,077 162,969 Commercial activities 80,810 87,572 Individual income tax and other taxes 34,550 30,083 Accrued general and administrative expenses 30,830 36,203 Other 33,473 19,165 Total 717,343 693,731 Other long-term liabilities consist of the following: As of September 30, December 31, 2024 2023 $ $ Deferred government grant income 32,429 34,204 Pension liability 13,022 14,995 Asset retirement obligation 1,140 1,127 Other 3,977 484 Total 50,568 50,810

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Debt	Debt The following table summarizes the Company’s short-term and long-term debt obligations as of September 30, 2024 and December 31, 2023: Lender Line of Credit Term Maturity Date Interest Rate As of September 30, 2024 December 31, 2023 $ RMB $ RMB China Construction Bank RMB580,000 9-year June 11, 2027 1 15,675 110,000 14,089 100,000 China Merchants Bank RMB350,000 9-year January 20, 2029 2 8,957 62,857 8,856 62,857 China Merchants Bank RMB378,000 9-year November 8, 2029 3 7,783 54,620 5,636 40,000 China Merchants Bank $380,000 1-year 4 380,000 2,666,667 300,000 2,129,321 China Minsheng Bank $150,000 1-year December 19, 2024 7.3% 150,000 1,052,632 150,000 1,064,660 China Industrial Bank RMB 675,000 364-day March 27, 2025 5 96,188 675,000 — — China Merchants Bank RMB 400,000 1-year June 5, 2025 3.0% 57,000 400,000 56,356 400,000 HSBC Bank RMB 340,000 1-year May 5, 2025 6 48,450 340,000 47,903 340,000 China Industrial Bank RMB 200,000 1-year May 29, 2024 — — — 28,177 200,000 Shanghai Pudong Development Bank RMB 700,000 1-year 7 2.9% 99,750 700,000 49,312 350,000 Other short-term debt 8 — — 28,037 199,000 Total short-term debt 863,803 6,061,776 688,366 4,885,838 China Construction Bank RMB580,000 9-year June 11, 2027 1 51,300 360,000 59,174 420,000 China Merchants Bank RMB350,000 9-year January 20, 2029 2 31,350 220,000 37,638 267,143 China Merchants Bank RMB378,000 9-year November 8, 2029 3 36,463 255,880 42,337 300,500 China CITIC Bank RMB480,000 10-year July 28, 2032 9 68,400 480,000 58,469 415,000 Total long-term bank loans 187,513 1,315,880 197,618 1,402,643 1 The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 4.2% as of September 30, 2024. The loan is secured by BeiGene Guangzhou Factory’s property ownership certificate and fixed assets. The Company repaid $6,886 (RMB50,000) during the nine months ended September 30, 2024. 2 The outstanding borrowings bear floating interest rates benchmarking against prevailing interest rates of certain PRC financial institutions. The loan interest rate was 3.7% as of September 30, 2024. The loan is secured by Guangzhou Factory’s second land use right and certain fixed assets in the second phase of the Guangzhou manufacturing facility’s build out. The Company repaid $6,526 (RMB47,143) during the nine months ended September 30, 2024. 3 The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.8% as of September 30, 2024. The loan is secured by fixed assets placed into service upon completion of the third phase of the Guangzhou manufacturing facility’s build out. The Company repaid $4,169 (RMB30,000) during the nine months ended September 30, 2024. 4 The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 6.7% as of September 30, 2024. $300,000 of the borrowings matures on December 25, 2024, and $80,000 matures on January 27, 2025. 5 The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 2.6% as of September 30, 2024. 6 The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 5.7% as of September 30, 2024. 7 $49,875 (RMB350,000) of the outstanding borrowings matures on November 21, 2024 and March 19, 2025, respectively. 8 During the two years ended December 31, 2023, the Company entered into short-term working capital loans with China Industrial Bank and China Merchants Bank to borrow up to RMB875,000 in aggregate. The Company repaid $27,476 (RMB199,000) during the nine months ended September 30, 2024. 9 In July 2022, the Company entered into a 10-year bank loan agreement with China CITIC Bank to borrow up to RMB480,000 at a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The Company drew down $9,053 (RMB65,000) during the nine months ended September 30, 2024. The weighted average loan interest rate was 3.7% as of September 30, 2024. The loan is secured by BeiGene Suzhou Co., Ltd.’s property ownership certificate of the small molecule manufacturing campus in Suzhou, China. The Company has numerous financial and non-financial covenants on its debt obligations with various banks and other lenders. Some of these covenants include cross-default provisions that could require acceleration of repayment of loans in the event of default. However, the Company’s debt is primarily short-term in nature. Any acceleration would be a matter of months but may impact the Company’s ability to refinance debt obligations if an event of default occurs. As of September 30, 2024, the Company was in compliance with all covenants of its material debt agreements. Interest Expense Interest expense recognized for the three and nine months ended September 30, 2024 was $14,312 and $39,949, respectively, among which, $8,176 and $25,697 was capitalized, respectively. Interest expense recognized for the three and nine months ended September 30, 2023 was $6,630 and $16,095, respectively, among which, $11,632 and $12,404 was capitalized, respectively.

Product Revenue

Product Revenue	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Product Revenue	Product Revenue The Company’s product revenue is primarily derived from the sale of its internally developed products BRUKINSA in the U.S., Europe, China, and other regions, and tislelizumab in China; XGEVA ® , BLINCYTO ® and KYPROLIS ® in China under a license from Amgen; and POBEVCY ® in China under a license from Bio-Thera. The table below presents the Company’s net product revenue for the three and nine months ended September 30, 2024 and 2023. Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Product revenue – gross 1,245,589 731,515 3,357,208 1,908,448 Less: Rebates and sales returns (252,142) (136,225) (695,697) (349,122) Product revenue – net 993,447 595,290 2,661,511 1,559,326 The following table disaggregates net product revenue by product for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ BRUKINSA ® 690,278 357,695 1,816,192 877,353 Tislelizumab 163,351 144,352 467,038 408,666 XGEVA ® 63,445 24,456 161,880 68,621 BLINCYTO ® 20,215 14,870 53,712 40,394 KYPROLIS ® 17,972 11,101 48,019 27,096 POBEVCY ® 12,193 14,130 40,398 41,894 REVLIMID ® 11,103 14,960 32,469 59,965 Other 14,890 13,726 41,803 35,337 Total product revenue – net 993,447 595,290 2,661,511 1,559,326 The following table presents the roll-forward of accrued revenue rebates and returns for the nine months ended September 30, 2024 and 2023: Nine Months Ended September 30, 2024 2023 $ $ Balance at beginning of the period 139,936 41,817 Accrual 695,697 349,122 Payments (621,886) (278,683) Balance at end of the period 213,747 112,256

(Loss) Earnings Per Share

(Loss) Earnings Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Loss (Earnings) Per Share	(Loss) Earnings Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted (loss) earnings per share: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Numerator: Net (loss) income (121,350) 215,413 (492,905) (514,155) Denominator: Weighted-average shares outstanding—basic 1,376,751,873 1,360,716,279 1,361,216,763 1,358,392,470 Effect of dilutive securities: Stock options, restricted stock units and ESPP shares — 29,615,554 — — Weighted-average shares outstanding—diluted 1,376,751,873 1,390,331,833 1,361,216,763 1,358,392,470 (Loss) earnings per share Basic (0.09) 0.16 (0.36) (0.38) Diluted (0.09) 0.15 (0.36) (0.38) For the three and nine months ended September 30, 2024 and the nine months ended September 30, 2023, the computation of basic loss per share using the two-class method was not applicable as the Company was in a net loss position, and the effects of all share options, restricted shares, restricted share units and ESPP shares were excluded from the calculation of diluted loss per share, as their effect would have been anti-dilutive.

Share-Based Compensation Expens

Share-Based Compensation Expense	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation Expense	Share-Based Compensation Expense Share Option and Incentive Plan During the nine months ended September 30, 2024, the Company granted options for 9,035,663 ordinary shares, restricted share units for 45,696,365 ordinary shares, and performance share units for 2,405,949 ordinary shares under the Company’s share option and incentive plan. As of September 30, 2024, options, restricted share units, and performance share units for ordinary shares outstanding totaled 65,461,567, 85,279,987, and 2,162,082, respectively. As of September 30, 2024, share-based awards to acquire 82,344,989 ordinary shares were available for future grant under the Company’s share option and incentive plan. Employee Share Purchase Plan The Company’s employee share purchase plan (the “ESPP”) allows eligible employees to purchase the Company’s ordinary shares (including in the form of ADSs) at the end of each offering period, which will generally be six months, at a 15% discount to the market price of the Company’s ADSs at the beginning or the end of each offering period, whichever is lower, using funds deducted from their payroll during the offering period. Eligible employees are able to authorize payroll deductions of up to 10% of their eligible earnings, subject to applicable limitations. As of September 30, 2024, 4,953,682 ordinary shares were available for future issuance under the ESPP. The following tables summarizes the shares issued under the ESPP: Market Price 1 Purchase Price 2 Issuance Date Number of Ordinary Shares Issued ADS Ordinary ADS Ordinary Proceeds August 31, 2024 1,035,996 $ 165.02 $ 12.69 $ 140.27 $ 10.78 $ 11,178 February 29, 2024 1,021,397 $ 165.65 $ 12.74 $ 140.80 $ 10.83 $ 11,063 August 31, 2023 794,144 $ 207.55 $ 15.97 $ 176.42 $ 13.57 $ 10,777 February 28, 2023 930,582 $ 171.10 $ 13.16 $ 145.44 $ 11.19 $ 10,414 1 The market price is the lower of the closing price on the Nasdaq Stock Market on the issuance date or the offering date, in accordance with the terms of the ESPP. 2 The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP. Share-Based Compensation Expense The following table summarizes total share-based compensation expense recognized for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Research and development 47,670 44,150 141,121 124,126 Selling, general and administrative 66,933 51,969 192,890 150,710 Total 114,603 96,119 334,011 274,836

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The movement of accumulated other comprehensive loss was as follows: Unrealized Foreign Currency Gains/(Losses) on Pension Translation Available-for-Sale Liability Adjustments Securities Adjustments Total $ $ $ $ Balance as of December 31, 2023 (87,987) 35 (11,494) (99,446) Other comprehensive income (loss) before reclassifications 15,348 (35) — 15,313 Amounts reclassified from accumulated other comprehensive loss — — 608 608 Net-current period other comprehensive income (loss) 15,348 (35) 608 15,921 Balance as of September 30, 2024 (72,639) — (10,886) (83,525)

Shareholders_ Equity

Shareholders’ Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Shareholders’ Equity	Shareholders’ Equity BMS Settlement On August 1, 2023, the Company entered into a Settlement and Termination Agreement (the “Settlement Agreement”) with BMS-Celgene and certain of its affiliates relating to the termination of the parties’ ongoing contractual relationships, the previously-disclosed ongoing arbitration proceeding concerning ABRAXANE ®

Restricted Net Assets

Restricted Net Assets	9 Months Ended
	Sep. 30, 2024
Restricted Net Assets Disclosure [Abstract]
Restricted Net Assets	Restricted Net Assets The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its PRC subsidiaries. Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s PRC subsidiaries only out of the subsidiary’s retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the condensed consolidated financial statements prepared in accordance with GAAP differ from those reflected in the statutory financial statements of the Company’s PRC subsidiaries. In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the board of directors, from the profits determined in accordance with the enterprise’s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company’s PRC subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits. As a result of these PRC laws and regulations, including the requirement to make annual appropriations of at least 10% of after-tax income and set aside as general reserve fund prior to payment of dividends, the Company’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments As of September 30, 2024, the Company had non-cancellable purchase commitments amounting to $155,852, of which $29,955 related to minimum purchase requirements for supply purchased from contract manufacturing organizations and $125,897 related to binding purchase obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen. Capital Commitments The Company had capital commitments amounting to $66,151 for the acquisition of property, plant and equipment as of September 30, 2024, related to various facilities across the globe, including the manufacturing and clinical R&D campus in Hopewell, New Jersey. Co-Development Funding Commitment Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global development costs for the Amgen oncology pipeline assets up to a total cap of $1,250,000. The Company is funding its portion of the co-development costs by contributing cash and development services. As of September 30, 2024, the Company’s remaining co-development funding commitment was $379,057. Funding Commitment The Company had committed capital related to two equity-method investments in the amount of $15,056. As of September 30, 2024, the remaining capital commitment was $8,156 and is expected to be paid from time to time over the investment period.

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance and allocates resources on a consolidated basis. The Company’s long-lived assets are primarily located in the U.S. and the PRC. Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from. Total revenues by geographic area are presented as follows: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ U.S. - total revenue 505,462 398,229 1,338,348 815,059 Product revenue 503,745 270,084 1,334,566 632,391 Collaboration revenue 1,717 128,145 3,782 182,668 China - total revenue 375,993 287,935 1,048,439 831,399 Product revenue 370,295 284,981 1,033,069 825,809 Collaboration revenue 5,698 2,954 15,370 5,590 Europe - total revenue 98,265 85,583 247,514 153,273 Product revenue 97,528 30,664 245,760 76,487 Collaboration revenue 737 54,919 1,754 76,786 Rest of world - total revenue 21,879 9,561 48,116 24,639 Product revenue 21,879 9,561 48,116 24,639 Collaboration revenue — — — — Total Revenue 1,001,599 781,308 2,682,417 1,824,370

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net (loss) income	$ (121,350)	$ (120,405)	$ (251,150)	$ 215,413	$ (381,137)	$ (348,431)	$ (492,905)	$ (514,155)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2024 shares	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		Name ( Title ) Action Taken ( Date of Action ) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities Dr. Xiaodong Wang (Co-Founder and Director) Adoption (August 12, 2024) Rule 10b5-1 trading arrangement Sale November 28, 2025 Stock options and restricted stock units (“RSUs”) equaling up to 334,795 American Depositary Shares (“ADSs”) plus additional sales of ADSs with an aggregate value of approximately US$3.5 million net of commissions and fees associated with the sales. Julia Wang (Former Chief Financial Officer) Termination (September 3, 2024) Rule 10b5-1 trading arrangement Sale September 3, 2024 78,727 ADSs plus an additional number of ADSs subject to RSUs equal to the net number of shares resulting from applicable RSU vestings after sell-to-cover for withholding tax.
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Dr. Xiaodong Wang [Member]
Trading Arrangements, by Individual
Name	Dr. Xiaodong Wang
Title	Co-Founder and Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 12, 2024
Expiration Date	November 28, 2025
Arrangement Duration	480 days
Aggregate Available	334,795	334,795
Julia Wang [Member]
Trading Arrangements, by Individual
Name	Julia Wang
Title	Former Chief Financial Officer
Rule 10b5-1 Arrangement Terminated	true
Termination Date	September 3, 2024
Aggregate Available	78,727	78,727

Description of Business, Basi_2

Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and the condensed consolidated statements of shareholders’ equity for the three and nine months ended September 30, 2024 and 2023, and the related footnote disclosures are unaudited. The accompanying unaudited interim condensed financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including guidance with respect to interim financial information and in conformity with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and determining the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates.
Recent accounting pronouncements	Recent accounting pronouncements New accounting standards which have not yet been adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which amended ASC 280. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. Single reportable segment entities are required to comply with all ASC 280 disclosure requirements. The Company will disclose descriptive information as required under ASC 280 and reference the consolidated financial statements in the segment and geographic information footnote for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis using the above input categories as of September 30, 2024 and December 31, 2023: Quoted Price in Active Market for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs As of September 30, 2024 (Level 1) (Level 2) (Level 3) $ $ $ Cash equivalents Money market funds 966,088 — — Prepaid expenses and other current assets: Convertible debt instrument — — 3,170 Other non-current assets (Note 4): Equity securities with readily determinable fair values 1,889 160 — Convertible debt instrument — — 4,995 Total 967,977 160 8,165 Quoted Price in Active Market for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs As of December 31, 2023 (Level 1) (Level 2) (Level 3) $ $ $ Cash equivalents Money market funds 1,052,149 — — Prepaid expenses and other current assets: U.S. Treasury securities 2,600 — — Convertible debt instrument — — 4,668 Other non-current assets (Note 4): Equity securities with readily determinable fair values 3,046 542 — Convertible debt instrument — — 4,215 Total 1,057,795 542 8,883

Collaborative and Licensing A_2

Collaborative and Licensing Arrangements (Tables)	9 Months Ended
	Sep. 30, 2024
Research and Development [Abstract]
Schedule of Net Product Sales	The following table summarizes total collaboration revenue recognized for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenue from Collaborators $ $ $ $ Research and development service revenue — 59,052 — 79,432 Right to access intellectual property revenue — 51,978 — 104,475 Material rights revenue — 71,980 — 71,980 Other 8,152 3,008 20,906 9,157 Total 8,152 186,018 20,906 265,044 The following table summarizes collaboration revenue recognized in connection with the China broad markets agreement for the three and nine months ended September 30, 2024 and the terminated ociperlimab option, collaboration and license agreement for the three and nine months ended September 30, 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 3,569 — 7,153 Right to access intellectual property revenue — 51,978 — 104,475 Material rights revenue — 71,980 71,980 China broad markets agreement 5,154 2,954 13,655 5,590 Total 5,154 130,481 13,655 189,198 The table below presents the Company’s net product revenue for the three and nine months ended September 30, 2024 and 2023. Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Product revenue – gross 1,245,589 731,515 3,357,208 1,908,448 Less: Rebates and sales returns (252,142) (136,225) (695,697) (349,122) Product revenue – net 993,447 595,290 2,661,511 1,559,326 The following table disaggregates net product revenue by product for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ BRUKINSA ® 690,278 357,695 1,816,192 877,353 Tislelizumab 163,351 144,352 467,038 408,666 XGEVA ® 63,445 24,456 161,880 68,621 BLINCYTO ® 20,215 14,870 53,712 40,394 KYPROLIS ® 17,972 11,101 48,019 27,096 POBEVCY ® 12,193 14,130 40,398 41,894 REVLIMID ® 11,103 14,960 32,469 59,965 Other 14,890 13,726 41,803 35,337 Total product revenue – net 993,447 595,290 2,661,511 1,559,326
Schedule of Collaboration Agreements	Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three and nine months ended September 30, 2024 and 2023 were as follows: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Research and development expense 17,015 16,321 52,981 39,595 Amortization of research and development cost share liability 16,575 15,900 51,614 38,569 Total amount due to Amgen for BeiGene’s portion of the development funding 33,590 32,221 104,595 78,164 As of September 30, 2024 $ Remaining portion of development funding cap 379,057 As of September 30, 2024 and December 31, 2023, the research and development cost share liability recorded in the Company’s balance sheet was as follows: As of September 30, December 31, 2024 2023 $ $ Research and development cost share liability, current portion 104,067 68,004 Research and development cost share liability, non-current portion 82,985 170,662 Total research and development cost share liability 187,052 238,666
Schedule of Amounts and Classification of Reimbursement Expense	The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three and nine months ended September 30, 2024 and 2023 as follows: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Cost of sales - product 10,278 3,159 28,437 4,343 Research and development (269) 431 (1,413) 1,743 Selling, general and administrative (21,641) (14,679) (60,894) (44,067) Total (11,632) (11,089) (33,870) (37,981)
Schedule of Payments Due to Collaboration Partners	Upfront and milestone payments incurred under these arrangements for the three and nine months ended September 30, 2024 and 2023 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or term of the commercialization agreements. Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Payments due to collaboration partners Classification $ $ $ $ Upfront payments Research and development expense — 15,000 27 15,000 Development milestones incurred Research and development expense 5,000 — 51,500 — Regulatory and commercial milestone payments Intangible asset — 9,379 — 18,612 Total 5,000 24,379 51,527 33,612

Restricted Cash and Investmen_2

Restricted Cash and Investments (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Restrictions on Cash and Cash Equivalents	The Company classifies restricted cash as current or non-current based on the term of the restriction. Restricted cash as of September 30, 2024 and December 31, 2023 was as follows: As of September 30, December 31, 2024 2023 $ $ Short-term restricted cash 9,284 11,473 Long-term restricted cash 2,211 2,711 Total 11,495 14,184
Schedule of Equity Method Investments	The following table summarizes the Company’s investments in equity securities: As of September 30, December 31, 2024 2023 $ $ Equity securities with readily determinable fair values 1 Fair value of Leap common stock 1,889 3,046 Fair value of Leap warrants 160 542 Equity securities without readily determinable fair values Pi Health, Inc. 2 40,798 — Other 55,159 55,860 Equity-method investments 35,233 25,981 Total 133,239 85,429 1 Represents common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (“Leap”). The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other income, net. 2 In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $38,063. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $40,798 and cash consideration of $1,000. The transaction resulted in a pre-tax gain of $3,735 recorded within other income, net during the nine months ended September 30, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company’s continuing operations. The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other income, net for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Equity securities with readily determinable fair values 494 (2,291) (1,539) (2,927) Equity securities without readily determinable fair values — (5,522) (797) (4,441) Equity-method investments (2,936) (2,675) (7,809) (5,299)

Inventories, Net (Tables)

Inventories, Net (Tables)	9 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	The Company’s inventories, net consisted of the following: As of September 30, December 31, 2024 2023 $ $ Raw materials 147,297 148,772 Work in process 61,985 39,098 Finished goods 222,394 228,252 Total inventories, net 431,676 416,122

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment, net are recorded at cost and consisted of the following: As of September 30, December 31, 2024 2023 $ $ Land 65,485 65,485 Building 608,004 231,656 Manufacturing equipment 249,371 186,856 Laboratory equipment 236,085 205,349 Leasehold improvement 60,728 60,124 Software, electronics and office equipment 83,814 83,281 Property, plant and equipment, at cost 1,303,487 832,751 Less: accumulated depreciation (366,165) (249,212) Construction in progress 625,643 740,615 Property, plant and equipment, net 1,562,965 1,324,154

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets Outstanding	Intangible assets as of September 30, 2024 and December 31, 2023 are summarized as follows: As of September 30, 2024 December 31, 2023 Gross Gross carrying Accumulated Intangible carrying Accumulated Intangible amount amortization assets, net amount amortization assets, net $ $ $ $ $ $ Finite-lived intangible assets: Developed products 64,811 (11,465) 53,346 64,274 (7,807) 56,467 Other 8,987 (8,394) 593 8,987 (8,316) 671 Total finite-lived intangible assets 73,798 (19,859) 53,939 73,261 (16,123) 57,138 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Amortization expense - Cost of sales - product 1,186 981 3,546 2,620 Amortization expense - Selling, general and administrative 78 1,287 78 1,662 Total 1,264 2,268 3,624 4,282
Schedule of Finite-Lived Intangible Assets Amortization Expense	Estimated amortization expense for each of the five succeeding years and thereafter, as of September 30, 2024 is as follows: Year Ending December 31, Cost of Sales - Product Selling, General and Administrative Total $ $ $ 2024 (remainder of year) 1,204 17 1,221 2025 4,812 67 4,879 2026 4,812 67 4,879 2027 4,812 67 4,879 2028 4,812 67 4,879 2029 and thereafter 32,894 308 33,202 Total 53,346 593 53,939

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Sep. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: As of September 30, December 31, 2024 2023 $ $ Prepaid research and development costs 60,227 60,476 Prepaid taxes 25,048 37,320 Other receivables 33,967 37,859 Prepaid manufacturing cost 28,849 42,066 Prepaid general and administrative expenses 16,183 14,619 Short-term restricted cash 9,284 11,473 Deposits 7,860 26,753 Prepaid insurance 6,180 8,872 Other current assets 21,482 18,027 Total 209,080 257,465
Schedule of Other Non-Current Assets	Other non-current assets consist of the following: As of September 30, December 31, 2024 2023 $ $ Prepayment of property and equipment 1 35,963 4,144 Prepaid supply cost 12,779 18,122 Rental deposits and other 9,180 8,195 Prepaid VAT 2,807 2,546 Long-term restricted cash 2,211 2,711 Long-term investments (Note 4) 138,234 89,644 Total 201,174 125,362 1 Includes payment for acquired land use right that was in the process of being transitioned to the Company as of September 30, 2024 (See Note 6).
Schedule of Accrued Expenses and Other Payables	Accrued expenses and other payables consist of the following: As of September 30, December 31, 2024 2023 $ $ Revenue rebates and returns related 213,747 139,936 Compensation related 211,856 217,803 External research and development activities related 112,077 162,969 Commercial activities 80,810 87,572 Individual income tax and other taxes 34,550 30,083 Accrued general and administrative expenses 30,830 36,203 Other 33,473 19,165 Total 717,343 693,731
Schedule of Other Long-Term Liabilities	Other long-term liabilities consist of the following: As of September 30, December 31, 2024 2023 $ $ Deferred government grant income 32,429 34,204 Pension liability 13,022 14,995 Asset retirement obligation 1,140 1,127 Other 3,977 484 Total 50,568 50,810

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Short-Term and Long-Term Debt Obligations	The following table summarizes the Company’s short-term and long-term debt obligations as of September 30, 2024 and December 31, 2023: Lender Line of Credit Term Maturity Date Interest Rate As of September 30, 2024 December 31, 2023 $ RMB $ RMB China Construction Bank RMB580,000 9-year June 11, 2027 1 15,675 110,000 14,089 100,000 China Merchants Bank RMB350,000 9-year January 20, 2029 2 8,957 62,857 8,856 62,857 China Merchants Bank RMB378,000 9-year November 8, 2029 3 7,783 54,620 5,636 40,000 China Merchants Bank $380,000 1-year 4 380,000 2,666,667 300,000 2,129,321 China Minsheng Bank $150,000 1-year December 19, 2024 7.3% 150,000 1,052,632 150,000 1,064,660 China Industrial Bank RMB 675,000 364-day March 27, 2025 5 96,188 675,000 — — China Merchants Bank RMB 400,000 1-year June 5, 2025 3.0% 57,000 400,000 56,356 400,000 HSBC Bank RMB 340,000 1-year May 5, 2025 6 48,450 340,000 47,903 340,000 China Industrial Bank RMB 200,000 1-year May 29, 2024 — — — 28,177 200,000 Shanghai Pudong Development Bank RMB 700,000 1-year 7 2.9% 99,750 700,000 49,312 350,000 Other short-term debt 8 — — 28,037 199,000 Total short-term debt 863,803 6,061,776 688,366 4,885,838 China Construction Bank RMB580,000 9-year June 11, 2027 1 51,300 360,000 59,174 420,000 China Merchants Bank RMB350,000 9-year January 20, 2029 2 31,350 220,000 37,638 267,143 China Merchants Bank RMB378,000 9-year November 8, 2029 3 36,463 255,880 42,337 300,500 China CITIC Bank RMB480,000 10-year July 28, 2032 9 68,400 480,000 58,469 415,000 Total long-term bank loans 187,513 1,315,880 197,618 1,402,643 1 The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 4.2% as of September 30, 2024. The loan is secured by BeiGene Guangzhou Factory’s property ownership certificate and fixed assets. The Company repaid $6,886 (RMB50,000) during the nine months ended September 30, 2024. 2 The outstanding borrowings bear floating interest rates benchmarking against prevailing interest rates of certain PRC financial institutions. The loan interest rate was 3.7% as of September 30, 2024. The loan is secured by Guangzhou Factory’s second land use right and certain fixed assets in the second phase of the Guangzhou manufacturing facility’s build out. The Company repaid $6,526 (RMB47,143) during the nine months ended September 30, 2024. 3 The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.8% as of September 30, 2024. The loan is secured by fixed assets placed into service upon completion of the third phase of the Guangzhou manufacturing facility’s build out. The Company repaid $4,169 (RMB30,000) during the nine months ended September 30, 2024. 4 The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 6.7% as of September 30, 2024. $300,000 of the borrowings matures on December 25, 2024, and $80,000 matures on January 27, 2025. 5 The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 2.6% as of September 30, 2024. 6 The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 5.7% as of September 30, 2024. 7 $49,875 (RMB350,000) of the outstanding borrowings matures on November 21, 2024 and March 19, 2025, respectively. 8 During the two years ended December 31, 2023, the Company entered into short-term working capital loans with China Industrial Bank and China Merchants Bank to borrow up to RMB875,000 in aggregate. The Company repaid $27,476 (RMB199,000) during the nine months ended September 30, 2024. 9 In July 2022, the Company entered into a 10-year bank loan agreement with China CITIC Bank to borrow up to RMB480,000 at a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The Company drew down $9,053 (RMB65,000) during the nine months ended September 30, 2024. The weighted average loan interest rate was 3.7% as of September 30, 2024. The loan is secured by BeiGene Suzhou Co., Ltd.’s property ownership certificate of the small molecule manufacturing campus in Suzhou, China.

Product Revenue (Tables)

Product Revenue (Tables)	9 Months Ended
	Sep. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Net Product Revenue	The following table summarizes total collaboration revenue recognized for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Revenue from Collaborators $ $ $ $ Research and development service revenue — 59,052 — 79,432 Right to access intellectual property revenue — 51,978 — 104,475 Material rights revenue — 71,980 — 71,980 Other 8,152 3,008 20,906 9,157 Total 8,152 186,018 20,906 265,044 The following table summarizes collaboration revenue recognized in connection with the China broad markets agreement for the three and nine months ended September 30, 2024 and the terminated ociperlimab option, collaboration and license agreement for the three and nine months ended September 30, 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 3,569 — 7,153 Right to access intellectual property revenue — 51,978 — 104,475 Material rights revenue — 71,980 71,980 China broad markets agreement 5,154 2,954 13,655 5,590 Total 5,154 130,481 13,655 189,198 The table below presents the Company’s net product revenue for the three and nine months ended September 30, 2024 and 2023. Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Product revenue – gross 1,245,589 731,515 3,357,208 1,908,448 Less: Rebates and sales returns (252,142) (136,225) (695,697) (349,122) Product revenue – net 993,447 595,290 2,661,511 1,559,326 The following table disaggregates net product revenue by product for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ BRUKINSA ® 690,278 357,695 1,816,192 877,353 Tislelizumab 163,351 144,352 467,038 408,666 XGEVA ® 63,445 24,456 161,880 68,621 BLINCYTO ® 20,215 14,870 53,712 40,394 KYPROLIS ® 17,972 11,101 48,019 27,096 POBEVCY ® 12,193 14,130 40,398 41,894 REVLIMID ® 11,103 14,960 32,469 59,965 Other 14,890 13,726 41,803 35,337 Total product revenue – net 993,447 595,290 2,661,511 1,559,326
Schedule of Accrued Revenue Rebates and Returns	The following table presents the roll-forward of accrued revenue rebates and returns for the nine months ended September 30, 2024 and 2023: Nine Months Ended September 30, 2024 2023 $ $ Balance at beginning of the period 139,936 41,817 Accrual 695,697 349,122 Payments (621,886) (278,683) Balance at end of the period 213,747 112,256

(Loss) Earnings Per Share (Tabl

(Loss) Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of the Computations of Basic and Diluted Loss (Earnings) Per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted (loss) earnings per share: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Numerator: Net (loss) income (121,350) 215,413 (492,905) (514,155) Denominator: Weighted-average shares outstanding—basic 1,376,751,873 1,360,716,279 1,361,216,763 1,358,392,470 Effect of dilutive securities: Stock options, restricted stock units and ESPP shares — 29,615,554 — — Weighted-average shares outstanding—diluted 1,376,751,873 1,390,331,833 1,361,216,763 1,358,392,470 (Loss) earnings per share Basic (0.09) 0.16 (0.36) (0.38) Diluted (0.09) 0.15 (0.36) (0.38)

Share-Based Compensation Expe_2

Share-Based Compensation Expense (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Shares Issued Under Employee Share Purchase Plan	The following tables summarizes the shares issued under the ESPP: Market Price 1 Purchase Price 2 Issuance Date Number of Ordinary Shares Issued ADS Ordinary ADS Ordinary Proceeds August 31, 2024 1,035,996 $ 165.02 $ 12.69 $ 140.27 $ 10.78 $ 11,178 February 29, 2024 1,021,397 $ 165.65 $ 12.74 $ 140.80 $ 10.83 $ 11,063 August 31, 2023 794,144 $ 207.55 $ 15.97 $ 176.42 $ 13.57 $ 10,777 February 28, 2023 930,582 $ 171.10 $ 13.16 $ 145.44 $ 11.19 $ 10,414 1 The market price is the lower of the closing price on the Nasdaq Stock Market on the issuance date or the offering date, in accordance with the terms of the ESPP. 2 The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP.
Schedule of Total Compensation Cost Recognized	The following table summarizes total share-based compensation expense recognized for the three and nine months ended September 30, 2024 and 2023: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ Research and development 47,670 44,150 141,121 124,126 Selling, general and administrative 66,933 51,969 192,890 150,710 Total 114,603 96,119 334,011 274,836

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	The movement of accumulated other comprehensive loss was as follows: Unrealized Foreign Currency Gains/(Losses) on Pension Translation Available-for-Sale Liability Adjustments Securities Adjustments Total $ $ $ $ Balance as of December 31, 2023 (87,987) 35 (11,494) (99,446) Other comprehensive income (loss) before reclassifications 15,348 (35) — 15,313 Amounts reclassified from accumulated other comprehensive loss — — 608 608 Net-current period other comprehensive income (loss) 15,348 (35) 608 15,921 Balance as of September 30, 2024 (72,639) — (10,886) (83,525)

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of Net Product Revenues by Geographic Area	Total revenues by geographic area are presented as follows: Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 $ $ $ $ U.S. - total revenue 505,462 398,229 1,338,348 815,059 Product revenue 503,745 270,084 1,334,566 632,391 Collaboration revenue 1,717 128,145 3,782 182,668 China - total revenue 375,993 287,935 1,048,439 831,399 Product revenue 370,295 284,981 1,033,069 825,809 Collaboration revenue 5,698 2,954 15,370 5,590 Europe - total revenue 98,265 85,583 247,514 153,273 Product revenue 97,528 30,664 245,760 76,487 Collaboration revenue 737 54,919 1,754 76,786 Rest of world - total revenue 21,879 9,561 48,116 24,639 Product revenue 21,879 9,561 48,116 24,639 Collaboration revenue — — — — Total Revenue 1,001,599 781,308 2,682,417 1,824,370

Description of Business, Basi_3

Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2024 medicine segment	Sep. 30, 2024 medicine segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of approved medicines | medicine	3	3
Number of operating segments | segment	1	1

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring Basis - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Quoted Price in Active Market for Identical Assets (Level 1)
Other non-current assets (Note 4):
Total	$ 967,977	$ 1,057,795
Quoted Price in Active Market for Identical Assets (Level 1) | U.S. Treasury securities
Prepaid expenses and other current assets:
U.S. Treasury securities		2,600
Quoted Price in Active Market for Identical Assets (Level 1) | Convertible debt instrument
Prepaid expenses and other current assets:
Convertible debt instrument	0	0
Other non-current assets (Note 4):
Convertible debt instrument	0	0
Quoted Price in Active Market for Identical Assets (Level 1) | Equity securities with readily determinable fair values
Other non-current assets (Note 4):
Equity securities without readily determinable fair values	1,889	3,046
Quoted Price in Active Market for Identical Assets (Level 1) | Money market funds
Assets at fair value on a recurring basis
Cash equivalents	966,088	1,052,149
Significant Other Observable Inputs (Level 2)
Other non-current assets (Note 4):
Total	160	542
Significant Other Observable Inputs (Level 2) | U.S. Treasury securities
Prepaid expenses and other current assets:
U.S. Treasury securities		0
Significant Other Observable Inputs (Level 2) | Convertible debt instrument
Prepaid expenses and other current assets:
Convertible debt instrument	0	0
Other non-current assets (Note 4):
Convertible debt instrument	0	0
Significant Other Observable Inputs (Level 2) | Equity securities with readily determinable fair values
Other non-current assets (Note 4):
Equity securities without readily determinable fair values	160	542
Significant Other Observable Inputs (Level 2) | Money market funds
Assets at fair value on a recurring basis
Cash equivalents	0	0
Significant Unobservable Inputs (Level 3)
Other non-current assets (Note 4):
Total	8,165	8,883
Significant Unobservable Inputs (Level 3) | U.S. Treasury securities
Prepaid expenses and other current assets:
U.S. Treasury securities		0
Significant Unobservable Inputs (Level 3) | Convertible debt instrument
Prepaid expenses and other current assets:
Convertible debt instrument	3,170	4,668
Other non-current assets (Note 4):
Convertible debt instrument	4,995	4,215
Significant Unobservable Inputs (Level 3) | Equity securities with readily determinable fair values
Other non-current assets (Note 4):
Equity securities without readily determinable fair values	0	0
Significant Unobservable Inputs (Level 3) | Money market funds
Assets at fair value on a recurring basis
Cash equivalents	$ 0	$ 0

Fair Value Measures and Disclos

Fair Value Measures and Disclosures - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Significant Unobservable Inputs (Level 3) | Convertible debt instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Losses on fair value adjustment	$ (1,802)	$ (1,664)
Quoted Price in Active Market for Identical Assets (Level 1) | Bank Time Deposits [Member] | Recurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 15,000	$ 15,000	$ 42,852

Collaborative and Licensing A_3

Collaborative and Licensing Arrangements - Schedule of Recognized Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Total revenues	$ 1,001,599	$ 781,308	$ 2,682,417	$ 1,824,370
Collaboration
Revenues
Total revenues	8,152	186,018	20,906	265,044
Collaboration | Novartis
Revenues
Total revenues	8,152	186,018	20,906	265,044
Collaboration | Ociperlimab
Revenues
Total revenues	5,154	130,481	13,655	189,198
Research and development service revenue | Novartis
Revenues
Total revenues	0	59,052	0	79,432
Research and development service revenue | Ociperlimab
Revenues
Total revenues	0	3,569	0	7,153
Right to access intellectual property revenue | Novartis
Revenues
Total revenues	0	51,978	0	104,475
Right to access intellectual property revenue | Ociperlimab
Revenues
Total revenues	0	51,978	0	104,475
Material rights revenue | Novartis
Revenues
Total revenues	0	71,980	0	71,980
Material rights revenue | Ociperlimab
Revenues
Total revenues	0	71,980		71,980
Other | Novartis
Revenues
Total revenues	8,152	3,008	20,906	9,157
China broad markets agreement | Ociperlimab
Revenues
Total revenues	$ 5,154	$ 2,954	$ 13,655	$ 5,590

Collaborative and Licensing A_4

Collaborative and Licensing Arrangements - Schedule of Funding Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Research and Development Arrangement, Contract to Perform for Others
Research and development expense	$ 496,179	$ 453,259	$ 1,411,283	$ 1,284,607
Amgen, Inc
Research and Development Arrangement, Contract to Perform for Others
Research and development expense	17,015	16,321	52,981	39,595
Amortization of research and development cost share liability	16,575	15,900	51,614	38,569
Total amount due to Amgen for BeiGene’s portion of the development funding	33,590	$ 32,221	104,595	$ 78,164
Remaining portion of development funding cap	$ 379,057		$ 379,057

Collaborative and Licensing A_5

Collaborative and Licensing Arrangements - Schedule of Financing Liability (Details) - Amgen, Inc - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Research and Development Arrangement, Contract to Perform for Others
Research and development cost share liability, current portion	$ 104,067	$ 68,004
Research and development cost share liability, non-current portion	82,985	170,662
Total research and development cost share liability	$ 187,052	$ 238,666

Collaborative and Licensing A_6

Collaborative and Licensing Arrangements - Schedule of Amounts and Classification of Payments (Income/(Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Research and Development Arrangement, Contract to Perform for Others
Total	$ (11,632)	$ (11,089)	$ (33,870)	$ (37,981)
Accounts payable	307,532		307,532		$ 315,111
Amgen, Inc | Collaborative Arrangement
Research and Development Arrangement, Contract to Perform for Others
Collaborative arrangement, inventory purchases	43,061	18,746	152,940	58,023
Amgen, Inc | Collaborative Arrangement | Related Party
Research and Development Arrangement, Contract to Perform for Others
Accounts payable	89,482		89,482		$ 55,474
Cost of sales - product
Research and Development Arrangement, Contract to Perform for Others
Total	10,278	3,159	28,437	4,343
Research and development
Research and Development Arrangement, Contract to Perform for Others
Total	(269)	431	(1,413)	1,743
Selling, general and administrative
Research and Development Arrangement, Contract to Perform for Others
Total	$ (21,641)	$ (14,679)	$ (60,894)	$ (44,067)

Collaborative Arrangements - Sc

Collaborative Arrangements - Schedule of In Licensing Agreements-Development (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative
Total	$ 5,000	$ 24,379	$ 51,527	$ 33,612
Upfront payments | Research and development expense
Collaborative Arrangement and Arrangement Other than Collaborative
Total	0	15,000	27	15,000
Development milestones incurred | Research and development expense
Collaborative Arrangement and Arrangement Other than Collaborative
Total	5,000	0	51,500	0
Regulatory and commercial milestone payments | Intangible asset
Collaborative Arrangement and Arrangement Other than Collaborative
Total	$ 0	$ 9,379	$ 0	$ 18,612

Restricted Cash and Investmen_3

Restricted Cash and Investments - Schedule of Restrictions on Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Short-term restricted cash	$ 9,284	$ 11,473
Long-term restricted cash	2,211	2,711
Total	$ 11,495	$ 14,184

Restricted Cash and Investmen_4

Restricted Cash and Investments - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule of Investments
Restricted cash	$ 11,495	$ 14,184
STAR Market | IPO
Schedule of Investments
Restricted cash	$ 787,147

Restricted Cash and Investmen_5

Restricted Cash and Investments - Investments In Equity Securities (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Schedule of Investments
Equity-method investments	$ 35,233	$ 35,233		$ 25,981
Total	133,239	133,239		85,429
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pi Health, Inc
Schedule of Investments
Net assets disposed of			$ 38,063
Proceeds from divestiture of businesses	1
Pre-tax gain		3,735
Leap Therapeutic, Inc | Ordinary Shares
Schedule of Investments
Equity securities with readily determinable fair values	1,889	1,889		3,046
Leap Therapeutic, Inc | Warrant
Schedule of Investments
Equity securities with readily determinable fair values	160	160		542
Pi Health, Inc
Schedule of Investments
Equity securities without readily determinable fair values	40,798	40,798		0
Other
Schedule of Investments
Equity securities without readily determinable fair values	$ 55,159	$ 55,159		$ 55,860

Restricted Cash and Investmen_6

Restricted Cash and Investments - Scheduled of Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Equity securities with readily determinable fair values	$ 494	$ (2,291)	$ (1,539)	$ (2,927)
Equity securities without readily determinable fair values	0	(5,522)	(797)	(4,441)
Equity-method investments	$ (2,936)	$ (2,675)	$ (7,809)	$ (5,299)

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 147,297	$ 148,772
Work in process	61,985	39,098
Finished goods	222,394	228,252
Total inventories, net	$ 431,676	$ 416,122

Property, Plant and Equipment_3

Property, Plant and Equipment, Net- Schedule of Property, Plant and Equipment, Net (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Property and equipment
Property, plant and equipment, at cost	$ 1,303,487,000	$ 832,751,000
Less: accumulated depreciation	(366,165,000)	(249,212,000)
Construction in progress	625,643,000	740,615,000
Property, plant and equipment, net	1,562,965,000	1,324,154,000
Land Located in Hopewell, NJ
Property and equipment
Property, plant and equipment, at cost	256,570,000
Land
Property and equipment
Property, plant and equipment, at cost	65,485,000	65,485,000
Land | Land Located in Hopewell, NJ
Property and equipment
Construction in progress	473,833,000
Building
Property and equipment
Property, plant and equipment, at cost	608,004,000	231,656,000
Manufacturing equipment
Property and equipment
Property, plant and equipment, at cost	249,371,000	186,856,000
Laboratory equipment
Property and equipment
Property, plant and equipment, at cost	236,085,000	205,349,000
Leasehold improvement
Property and equipment
Property, plant and equipment, at cost	60,728,000	60,124,000
Software, electronics and office equipment
Property and equipment
Property, plant and equipment, at cost	$ 83,814,000	$ 83,281,000

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Narratives (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	May 31, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Property, Plant and Equipment
Property, plant and equipment, at cost			$ 1,303,487,000		$ 1,303,487,000		$ 832,751,000
Construction in progress			625,643,000		625,643,000		740,615,000
Purchases of property, plant and equipment					400,183,000	$ 404,937,000
Depreciation expense			70,028,000	$ 19,242,000	117,892,000	$ 59,574,000
Tislelizumab
Property, Plant and Equipment
Accelerated depreciation expense			41,808,000		41,808,000
Shanghai, China
Property, Plant and Equipment
Purchases of property, plant and equipment		$ 75,986,000
Land
Property, Plant and Equipment
Property, plant and equipment, at cost			65,485,000		65,485,000		$ 65,485,000
Land | Shanghai, China
Property, Plant and Equipment
Purchases of property, plant and equipment		29,721,000
Construction in progress
Property, Plant and Equipment
Purchases of property, plant and equipment	$ 23,443,000
Construction in progress | Shanghai, China
Property, Plant and Equipment
Purchases of property, plant and equipment		$ 46,265,000
Land Located in Hopewell, NJ
Property, Plant and Equipment
Property, plant and equipment, at cost			256,570,000		256,570,000
Land Located in Hopewell, NJ | Land
Property, Plant and Equipment
Construction in progress			$ 473,833,000		$ 473,833,000

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets Outstanding (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Finite-lived intangible assets:
Gross carrying amount	$ 73,798	$ 73,261
Accumulated amortization	(19,859)	(16,123)
Total	53,939	57,138
Developed products
Finite-lived intangible assets:
Gross carrying amount	64,811	64,274
Accumulated amortization	(11,465)	(7,807)
Total	53,346	56,467
Other
Finite-lived intangible assets:
Gross carrying amount	8,987	8,987
Accumulated amortization	(8,394)	(8,316)
Total	$ 593	$ 671

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details) - Weighted Average	Sep. 30, 2024
Developed products
Acquired Finite-Lived Intangible Assets
Useful life	12 years
Other
Acquired Finite-Lived Intangible Assets
Useful life	12 years

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Finite-Lived Intangible Assets
Amortization of intangible assets	$ 1,264	$ 2,268	$ 3,624	$ 4,282
Cost of sales - product
Finite-Lived Intangible Assets
Amortization of intangible assets	1,186	981	3,546	2,620
Selling, general and administrative
Finite-Lived Intangible Assets
Amortization of intangible assets	$ 78	$ 1,287	$ 78	$ 1,662

Intangible Assets - Schedule _3

Intangible Assets - Schedule of Expected Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Acquired Finite-Lived Intangible Assets
2024 (remainder of year)	$ 1,221
2025	4,879
2026	4,879
2027	4,879
2028	4,879
2029 and thereafter	33,202
Total	53,939	$ 57,138
Cost of Sales - Product
Acquired Finite-Lived Intangible Assets
2024 (remainder of year)	1,204
2025	4,812
2026	4,812
2027	4,812
2028	4,812
2029 and thereafter	32,894
Total	53,346
Selling, general and administrative
Acquired Finite-Lived Intangible Assets
2024 (remainder of year)	17
2025	67
2026	67
2027	67
2028	67
2029 and thereafter	308
Total	$ 593

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income taxes
Income tax expense	$ 23,046	$ 13,925	$ 45,255	$ 39,091
Unrecognized tax benefits	17,592		17,592
Increase in uncertain tax position	$ 1,788		$ 3,328

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Prepaid expenses and other current assets
Prepaid research and development costs	$ 60,227	$ 60,476
Prepaid taxes	25,048	37,320
Other receivables	33,967	37,859
Prepaid manufacturing cost	28,849	42,066
Prepaid general and administrative expenses	16,183	14,619
Short-term restricted cash	9,284	11,473	$ 11,548
Deposits	7,860	26,753
Prepaid insurance	6,180	8,872
Other current assets	21,482	18,027
Total	$ 209,080	$ 257,465

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Schedule of Other Non-current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Other non-current assets
Prepayment of property and equipment	$ 35,963	$ 4,144
Prepaid supply cost	12,779	18,122
Rental deposits and other	9,180	8,195
Prepaid VAT	2,807	2,546
Long-term restricted cash	2,211	2,711
Long-term investments (Note 4)	138,234	89,644
Total	$ 201,174	$ 125,362

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Payables (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accrued expenses and other payables
Revenue rebates and returns related	$ 213,747	$ 139,936
Compensation related	211,856	217,803
External research and development activities related	112,077	162,969
Commercial activities	80,810	87,572
Individual income tax and other taxes	34,550	30,083
Accrued general and administrative expenses	30,830	36,203
Other	33,473	19,165
Total	$ 717,343	$ 693,731

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Other long-term liabilities
Deferred government grant income	$ 32,429	$ 34,204
Pension liability	13,022	14,995
Asset retirement obligation	1,140	1,127
Other	3,977	484
Total	$ 50,568	$ 50,810

Debt - Schedule of Short-term a

Debt - Schedule of Short-term and Long-term Debt Obligations (Details)	1 Months Ended	9 Months Ended
	Jul. 31, 2022	Sep. 30, 2024 USD ($)	Sep. 30, 2024 CNY (¥)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CNY (¥)
Debt Instrument
Short-term debt		$ 863,803,000	¥ 6,061,776,000	$ 688,366,000	¥ 4,885,838,000
Long-term debt		$ 187,513,000	1,315,880,000	197,618,000	1,402,643,000
Loans Payable
Debt Instrument
Line of Credit					875,000,000
China Industrial Bank | Loans Payable
Debt Instrument
Interest Rate		2.60%
Short Term Bank Loan Dated April 4 2018 | China Construction Bank | Loans Payable
Debt Instrument
Line of Credit			580,000
Term		9 years
Short-term debt		$ 15,675,000	110,000,000	14,089,000	100,000,000
Short Term Bank Loan Dated January 22, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit			350,000
Term		9 years
Interest Rate		3.70%
Short-term debt		$ 8,957,000	62,857,000	8,856,000	62,857,000
Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Interest Rate		3.80%
Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit			378,000,000
Term		9 years
Short-term debt		$ 7,783,000	54,620,000	5,636,000	40,000,000
Short Term Bank Loan Dated July 28, 2023 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit | $		$ 380,000,000
Term		1 year
Short-term debt		$ 380,000,000	2,666,667,000	300,000,000	2,129,321,000
Short Term Bank Loan Dated July 28, 2023 | China Minsheng Bank | Loans Payable
Debt Instrument
Interest Rate		6.70%
Short Term Bank Loan Dated December 20, 2023 | China Minsheng Bank | Loans Payable
Debt Instrument
Line of Credit | $		$ 150,000,000
Term		1 year
Interest Rate		7.30%
Short-term debt		$ 150,000,000	1,052,632,000	150,000,000	1,064,660,000
Short Term Bank Loan Dated March 21, 2024 | China Industrial Bank | Loans Payable
Debt Instrument
Line of Credit			675,000
Term		364 days
Short-term debt		$ 96,188,000	675,000,000	0	0
Short Term Bank Loan Dated June 5 2023 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit			400,000
Term		1 year
Interest Rate		3%
Short-term debt		$ 57,000,000	400,000,000	56,356,000	400,000,000
Short Term Bank Loan Dated May 4 2023 | HSBC Bank | Loans Payable
Debt Instrument
Line of Credit			340,000
Term		1 year
Interest Rate		5.70%
Short-term debt		$ 48,450,000	340,000,000	47,903,000	340,000,000
Short Term Bank Loan Dated May 30 2023 | China Industrial Bank | Loans Payable
Debt Instrument
Line of Credit			200,000
Term		1 year
Interest Rate		0%
Short-term debt		$ 0	0	28,177,000	200,000,000
Short Term Bank Loan Dated November 14, 2023 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Line of Credit			700,000
Term		1 year
Interest Rate		2.90%
Short-term debt		$ 99,750,000	700,000,000	49,312,000	350,000,000
Long Term Bank Loan Dated April 4, 2018 | China Construction Bank | Loans Payable
Debt Instrument
Line of Credit			580,000
Term		9 years
Interest Rate		4.20%
Long-term debt		$ 51,300,000	360,000,000	59,174,000	420,000,000
Long Term Bank Loan Dated January 22, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit			350,000
Term		9 years
Long-term debt		$ 31,350,000	220,000,000	37,638,000	267,143,000
Long Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit			378,000
Term		9 years
Long-term debt		$ 36,463,000	255,880,000	42,337,000	300,500,000
Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank
Debt Instrument
Line of Credit			480,000,000
Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank | Loans Payable
Debt Instrument
Line of Credit			480,000
Term	10 years	10 years
Long-term debt		$ 68,400,000	480,000,000	58,469,000	415,000,000
Short Term Bank Loan Dated November 21, 2024 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Short-term debt		49,875,000	350,000,000
Short Term Bank Loan Dated March 19, 2025 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Short-term debt		49,875,000	350,000,000
Other Short Term Debt | Loans Payable
Debt Instrument
Short-term debt		$ 0	¥ 0	$ 28,037,000	¥ 199,000,000

Debt - Footnotes (Details)

Debt - Footnotes (Details)	1 Months Ended	9 Months Ended
	Jul. 31, 2022	Sep. 30, 2024 USD ($)	Sep. 30, 2024 CNY (¥)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 CNY (¥)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CNY (¥)
Debt Instrument
Repayment of short-term loans | $		$ 157,490,000		$ 159,576,000
Repayments of long-term debt | $		17,581,000		8,462,000
Short-term debt		863,803,000			¥ 6,061,776,000	$ 688,366,000	¥ 4,885,838,000
Proceeds from long-term loan | $		$ 9,053,000		$ 22,502,000
Loans Payable
Debt Instrument
Line of credit							875,000,000
China Industrial Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period		2.60%	2.60%
Long Term Bank Loan Dated April 4, 2018 | China Construction Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period		4.20%	4.20%
Repayment of short-term loans		$ 6,886,000	¥ 50,000,000
Line of credit					580,000
Debt instrument term (in years)		9 years	9 years
Short Term Bank Loan Dated January 22, 2020 | China Construction Bank | Loans Payable
Debt Instrument
Repayment of short-term loans		$ 6,526,000	¥ 47,143,000
Short Term Bank Loan Dated January 22, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period		3.70%	3.70%
Short-term debt		$ 8,957,000			62,857,000	8,856,000	62,857,000
Line of credit					350,000
Debt instrument term (in years)		9 years	9 years
Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Repayments of long-term debt		$ 4,169,000	¥ 30,000,000
Short-term debt		$ 7,783,000			54,620,000	5,636,000	40,000,000
Line of credit					378,000,000
Debt instrument term (in years)		9 years	9 years
Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period		3.80%	3.80%
Short Term Bank Loan Dated July 28, 2023 | China Merchants Bank | Loans Payable
Debt Instrument
Short-term debt		$ 380,000,000			2,666,667,000	300,000,000	2,129,321,000
Line of credit | $		$ 380,000,000
Debt instrument term (in years)		1 year	1 year
Short Term Bank Loan Dated July 28, 2023 | China Minsheng Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period		6.70%	6.70%
Short Term Bank Loan Maturing December252024 | China Minsheng Bank | Loans Payable
Debt Instrument
Short-term debt | $		$ 300,000,000
Short Term Bank Loan Maturing January 27, 2025 | China Minsheng Bank | Loans Payable
Debt Instrument
Short-term debt | $		$ 80,000,000
Short Term Bank Loan Dated May 4 2023 | HSBC Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period		5.70%	5.70%
Short-term debt		$ 48,450,000			340,000,000	47,903,000	340,000,000
Line of credit					340,000
Debt instrument term (in years)		1 year	1 year
Short Term Bank Loan Dated November 21, 2024 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Short-term debt		$ 49,875,000			350,000,000
Short Term Bank Loan Dated March 19, 2025 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Short-term debt		49,875,000			350,000,000
Other Short Term Debt | Loans Payable
Debt Instrument
Repayment of short-term loans		27,476,000	¥ 199,000,000
Short-term debt		$ 0			¥ 0	$ 28,037,000	¥ 199,000,000
Long Term Bank Loan Dated July 29, 2022 | China Merchants Bank | Loans Payable
Debt Instrument
Fixed annual interest rate (as a percent)		3.70%			3.70%
Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank
Debt Instrument
Line of credit					¥ 480,000,000
Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank | Loans Payable
Debt Instrument
Line of credit					¥ 480,000
Debt instrument term (in years)	10 years	10 years	10 years
Proceeds from long-term loan		$ 9,053,000	¥ 65,000,000

Debt - Narratives (Details)

Debt - Narratives (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Disclosure [Abstract]
Interest expense	$ 14,312	$ 6,630	$ 39,949	$ 16,095
Interest capitalized	$ 8,176	$ 11,632	$ 25,697	$ 12,404

Product Revenue - Schedule of N

Product Revenue - Schedule of Net Product Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Product revenue – net	$ 1,001,599	$ 781,308	$ 2,682,417	$ 1,824,370
Product revenue
Revenues
Product revenue – gross	1,245,589	731,515	3,357,208	1,908,448
Less: Rebates and sales returns	(252,142)	(136,225)	(695,697)	(349,122)
Product revenue – net	993,447	595,290	2,661,511	1,559,326
Product revenue | BRUKINSA®
Revenues
Product revenue – net	690,278	357,695	1,816,192	877,353
Product revenue | Tislelizumab
Revenues
Product revenue – net	163,351	144,352	467,038	408,666
Product revenue | XGEVA®
Revenues
Product revenue – net	63,445	24,456	161,880	68,621
Product revenue | BLINCYTO®
Revenues
Product revenue – net	20,215	14,870	53,712	40,394
Product revenue | KYPROLIS®
Revenues
Product revenue – net	17,972	11,101	48,019	27,096
Product revenue | POBEVCY®
Revenues
Product revenue – net	12,193	14,130	40,398	41,894
Product revenue | REVLIMID®
Revenues
Product revenue – net	11,103	14,960	32,469	59,965
Product revenue | Other
Revenues
Product revenue – net	$ 14,890	$ 13,726	$ 41,803	$ 35,337

Product Revenue - Schedule of A

Product Revenue - Schedule of Accrued Revenue Rebates and Returns (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Accrued Sales Rebates and Returns
Balance at beginning of the period	$ 139,936
Balance at end of the period	213,747
Product revenue
Accrued Sales Rebates and Returns
Balance at beginning of the period	139,936	$ 41,817
Accrual	695,697	349,122
Payments	(621,886)	(278,683)
Balance at end of the period	$ 213,747	$ 112,256

(Loss) Earnings Per Share - Sch

(Loss) Earnings Per Share - Schedule of the Computations of Basic and Diluted Loss (Earnings) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Net (loss) income	$ (121,350)	$ (120,405)	$ (251,150)	$ 215,413	$ (381,137)	$ (348,431)	$ (492,905)	$ (514,155)
Denominator:
Weighted-average shares outstanding—basic (in shares)	1,376,751,873			1,360,716,279			1,361,216,763	1,358,392,470
Effect of dilutive securities:
Stock options, restricted stock units and ESPP shares (in shares)	0			29,615,554			0	0
Weighted-average shares outstanding— diluted (in shares)	1,376,751,873			1,390,331,833			1,361,216,763	1,358,392,470
(Loss) earnings per share
Basic (in dollars per share)	$ (0.09)			$ 0.16			$ (0.36)	$ (0.38)
Diluted (in dollars per share)	$ (0.09)			$ 0.15			$ (0.36)	$ (0.38)

Share-Based Compensation Expe_3

Share-Based Compensation Expense - Narrative (Details) - shares	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2018
2016 Share Option and Incentive Plan | Share Options
Share-based Compensation Arrangement by Share-based Payment Award
Granted (in shares)	9,035,663
Number of options outstanding (in shares)	65,461,567
2016 Share Option and Incentive Plan | Restricted Share Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award
Granted (in shares)	45,696,365
Number of options outstanding (in shares)	85,279,987
2016 Share Option and Incentive Plan | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award
Granted (in shares)	2,405,949
Number of options outstanding (in shares)	2,162,082
2016 Share Option and Incentive Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award
Shares available for future grants (in shares)	82,344,989
Employee Share Purchase Plan 2018
Share-based Compensation Arrangement by Share-based Payment Award
Shares available for future grants (in shares)	4,953,682
Offering period	6 months
Discount on purchase price of common stock (as a percent)		15%
Maximum percentage of eligible earnings as after-tax withholdings to purchase ordinary shares (as a percent)	10%

Share-Based Compensation Expe_4

Share-Based Compensation Expense - Schedule of Shares Issued Under Employee Share Purchase Plan (Details) - Employee Share Purchase Plan 2018 - USD ($) $ / shares in Units, $ in Thousands	Aug. 31, 2024	Feb. 29, 2024	Aug. 31, 2023	Feb. 28, 2023
Share-based Compensation Arrangement by Share-based Payment Award
Number of Ordinary Shares Issued ( in shares)	1,035,996	1,021,397	794,144	930,582
Market Price, ADS (in dollars per share)	$ 165.02	$ 165.65	$ 207.55	$ 171.10
Market Price, Ordinary (in dollars per share)	12.69	12.74	15.97	13.16
Purchase Price, ADS (in dollars per share)	140.27	140.80	176.42	145.44
Purchase Price, Ordinary (in dollars per share)	$ 10.78	$ 10.83	$ 13.57	$ 11.19
Proceeds	$ 11,178	$ 11,063	$ 10,777	$ 10,414

Share-Based Compensation Expe_5

Share-Based Compensation Expense - Schedule of Total Compensation Cost Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based compensation
Compensation expense	$ 114,603	$ 96,119	$ 334,011	$ 274,836
Research and development
Share-based compensation
Compensation expense	47,670	44,150	141,121	124,126
Selling, general and administrative
Share-based compensation
Compensation expense	$ 66,933	$ 51,969	$ 192,890	$ 150,710

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024
Movement in accumulated other comprehensive loss
Balance at the beginning of period	$ 3,366,255	$ 3,360,361	$ 3,537,327	$ 3,798,559	$ 4,157,306	$ 4,383,355	$ 3,537,327
Other comprehensive income (loss) before reclassifications							15,313
Amounts reclassified from accumulated other comprehensive loss							608
Net-current period other comprehensive income (loss)	56,949	(8,830)	(32,198)	(1,244)	(84,673)	18,403	15,921
Balance at the end of period	3,436,073	3,366,255	3,360,361	3,763,234	3,798,559	4,157,306	3,436,073
Accumulated Other Comprehensive Loss
Movement in accumulated other comprehensive loss
Balance at the beginning of period	(140,474)	(131,644)	(99,446)	(143,687)	(59,014)	(77,417)	(99,446)
Net-current period other comprehensive income (loss)	56,949	(8,830)	(32,198)	(1,244)	(84,673)	18,403
Balance at the end of period	(83,525)	$ (140,474)	(131,644)	$ (144,931)	$ (143,687)	$ (59,014)	(83,525)
Foreign Currency Translation Adjustments
Movement in accumulated other comprehensive loss
Balance at the beginning of period			(87,987)				(87,987)
Other comprehensive income (loss) before reclassifications							15,348
Amounts reclassified from accumulated other comprehensive loss							0
Net-current period other comprehensive income (loss)							15,348
Balance at the end of period	(72,639)						(72,639)
Unrealized Gains (Losses) on Available-for-Sale Securities
Movement in accumulated other comprehensive loss
Balance at the beginning of period			35				35
Other comprehensive income (loss) before reclassifications							(35)
Amounts reclassified from accumulated other comprehensive loss							0
Net-current period other comprehensive income (loss)							(35)
Balance at the end of period	0						0
Pension Liability Adjustments
Movement in accumulated other comprehensive loss
Balance at the beginning of period			$ (11,494)				(11,494)
Other comprehensive income (loss) before reclassifications							0
Amounts reclassified from accumulated other comprehensive loss							608
Net-current period other comprehensive income (loss)							608
Balance at the end of period	$ (10,886)						$ (10,886)

Shareholders_ Equity (Details)

Shareholders’ Equity (Details) - USD ($) $ in Thousands			3 Months Ended
	Aug. 15, 2023	Aug. 01, 2023	Sep. 30, 2023
Subsidiary, Sale of Stock
Cancellation of ordinary shares			$ 362,917
Ordinary Shares
Subsidiary, Sale of Stock
Cancellation of ordinary shares (in share)		23,273,108	23,273,108
Cancellation of ordinary shares			$ 2
Total
Subsidiary, Sale of Stock
Cancellation of ordinary shares	$ 362,917

Restricted Net Assets (Details)

Restricted Net Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Segment Reporting Information
Minimum required statutory reserve of annual after-tax profit (as a percent)	10%
Required statutory reserve as a percentage of registered capital (as a percent)	50%
Cash and cash equivalents	$ 2,701,933	$ 3,171,800	$ 3,067,336
China
Segment Reporting Information
Cash and cash equivalents	$ 1,391,444	$ 1,837,790

Commitments and Contingencies -

Commitments and Contingencies - Commitments (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) investment
Purchase and Capital commitments
Purchase commitments	$ 155,852
Investments Funding Commitment
Purchase and Capital commitments
Other commitments	$ 8,156
Number of equity investments | investment	2
Maximum commitment	$ 15,056
Amgen, Inc
Purchase and Capital commitments
Other commitments	379,057
Maximum cash and development services commitment	1,250,000
Minimum Purchase Commitments For Supply Purchased
Purchase and Capital commitments
Purchase commitments	29,955
Inventories
Purchase and Capital commitments
Purchase commitments	125,897
Capital Addition Purchase Commitments
Purchase and Capital commitments
Other commitments	$ 66,151

Segment and Geographic Inform_3

Segment and Geographic Information - Narratives (Details) - segment	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Segment Reporting [Abstract]
Number of operating segments	1	1

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net product revenues by geographic area
Total Revenue	$ 1,001,599	$ 781,308	$ 2,682,417	$ 1,824,370
U.S. - total revenue
Net product revenues by geographic area
Total Revenue	505,462	398,229	1,338,348	815,059
China - total revenue
Net product revenues by geographic area
Total Revenue	375,993	287,935	1,048,439	831,399
Europe - total revenue
Net product revenues by geographic area
Total Revenue	98,265	85,583	247,514	153,273
Rest of world - total revenue
Net product revenues by geographic area
Total Revenue	21,879	9,561	48,116	24,639
Product revenue
Net product revenues by geographic area
Total Revenue	993,447	595,290	2,661,511	1,559,326
Product revenue | U.S. - total revenue
Net product revenues by geographic area
Total Revenue	503,745	270,084	1,334,566	632,391
Product revenue | China - total revenue
Net product revenues by geographic area
Total Revenue	370,295	284,981	1,033,069	825,809
Product revenue | Europe - total revenue
Net product revenues by geographic area
Total Revenue	97,528	30,664	245,760	76,487
Product revenue | Rest of world - total revenue
Net product revenues by geographic area
Total Revenue	21,879	9,561	48,116	24,639
Collaboration revenue
Net product revenues by geographic area
Total Revenue	8,152	186,018	20,906	265,044
Collaboration revenue | U.S. - total revenue
Net product revenues by geographic area
Total Revenue	1,717	128,145	3,782	182,668
Collaboration revenue | China - total revenue
Net product revenues by geographic area
Total Revenue	5,698	2,954	15,370	5,590
Collaboration revenue | Europe - total revenue
Net product revenues by geographic area
Total Revenue	737	54,919	1,754	76,786
Collaboration revenue | Rest of world - total revenue
Net product revenues by geographic area
Total Revenue	$ 0	$ 0	$ 0	$ 0